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Department of Immunology, Research Institute of S cripps Clinic, La J olla, California, U.S.A . 
Cell injury by complement occurs as a consequence of 
activation of eithe r the classical or the a lternative path-
way on t he surface of a cell. It is accomplished by the 
membrane att ack complex (MAC) . Its precursor pro-
teins, C5, C6, C7, C8, and C9, are h ydrophilic glycopro-
teins with M r ranging from 70,000-180,000. When C5 
is cleaved by the serine protease C5 convertase which 
covalently attaches to target cells, nascent C5b is pro-
duced and forms together with C6 a soluble and stable 
bimolecular complex (C5b,6) . Upon binding of C5b,6 to 
C7 a trimolecular complex (C5b-7) is formed which 
expresses a metastable membrane-binding site. Mem-
brane-bound C5b-7 constitutes the receptor for C8 and 
the tetramolecular C5b-8 complex binds a nd poly mer-
izes C9. During the assembly process the proteins 
undergo h ydrophilic-amphiphilic transition and the end 
product consis ts of C5b-8 (Mr approximately 550,000) 
and of tubular poly C9 (Mr approximately 1,100,000). 
The functional channel size va ries but its maxima l di-
ameter is approximately 100 A. C9 polymerization ap-
pears to involve initial reversible association of several 
C9 molecules which is followed by temperature-depend-
ent, constrained unfolding. Unfolded C9 monomers the n 
associate laterally with each other and polymerization 
terminates with closure of the circular s tructure which 
consists of 12-18 C9 monomers. Amino acid composition 
and sequence indicate that the N-terminal half of the 
single chain C9 molecule is hydrophilic and the C-ter-
minal half rather hydrophobic. Phospholipid-binding 
and insertion into membranes are functions of the C-
terminal portion of the molecule. Control of the MAC is 
exerted by the S -protein (Mr 80,000) which binds to the 
forming complex and prevents its attachment to t he cell 
membrane. Control is also exe rted by certa in species-
specific membrane proteins w hich inte rfere with C5 
convertase a nd C9 function. 
Cell injury by complement occurs as a consequence of acti-
vation of either the classical or t he alternative pathway on the 
surface of a ce ll. T he "ki ller molecule" is t he membrane attack 
complex (MAC). It constitutes a supramolecular organization 
that is composed of approx imately 20 protein molecules and 
has a M , of about 1, 700,000. The complex has 5 precursors, C5, 
C6, C7, C8, and C9, which are hydrophilic glycoproteins wit h 
M, ranging from 70,000- 180,000. When C5 is cleaved by C5 
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convertase and nascent C5b (5b*) is produced, self-assembly of 
the MAC ensues: C5b* and C6 form a soluble and stable 
bimolecula r complex which binds to C7 and induces it to 
express a metastable si te through which t he nascent complex 
(C5b-7*) can bind to membranes. Membrane-bound C5b-7 
constitutes the receptor for C8 and the C5b-8 complex binds 
and polymerizes C9. During the assembly process t he proteins 
undergo hydrophilic-amphiphilic t ransit ion. Thus, metastable 
C5b-7 expresses hydrophobic phospholipid-binding sites. The 
lipid-binding capacity increases on addi t ion of C8 and again on 
addit ion of C9. The fully assembled MAC contains one molecule 
of C5b, C6, C7, and C8 and mult iple molecules of C9. The end-
product consists of the tetramolecular C5b-8 complex (M , 
approximately 550,000) and of tubular poly C9 (M, approxi-
mately 1,100,000). The available evidence suggests that poly 
C9 represents the major complement transmembrane channel 
and C5b-8 t he uni t t hat catalyzes C9 polymerizat ion (Fig 1). 
Structura l and functional membrane perturbation begins 
before the la rge poly C9 channel is formed. In absence of C9, 
the C5b-8 complex tends to aggregate in the target membrane 
and t hese la rge protein aggregates produce membrane leaki-
ness. Aggregat ion also occurs in p resence of C9 when t he 
amount of C9 is insufficient for poly C9 formation. W hereas 
the poly C9 channel is not necessary fo r complement-dependent 
lysis of erythrocytes, it may be essent ial for the killing of 
nucleated ce lls. 
In t he electron microscope the MAC projects t he image of a 
hollow cylinder and, ipserted into a target membrane, it evokes 
t he image of a 100 A-wide circular membrane hole which is 
surrounded by a 50 A-wide rim. These characteristic and well 
known images of the MAC and the membrane lesions produced 
by complement are by and large due to the tubular poly C9 
contained in t he MAC. 
MAC fo rmation in t he fluid phase is controlled by the S-
protein , a 80,000 da lton plasma glycoprotein which functions 
as MAC inhibitor. It binds to the metastable binding site of 
C5b-7* and thereby prevents membrane attack. SC5b-7 re-
mains in the fluid phase as a hydrophilic complex. Whereas the 
S-protein wit hin the complex does not block the attachment of 
C8 and C9, it limits the number of C9 molecules to 2 or 3 and 
inhibits C9 polymerization (Fig 1). 
Some of the propert ies of the proteins of the membrane 
attack pathway are listed in T able I. 
THE C5 ACTIVATING ENZYMES 
The classical C5 convertase, C4b,2a,3b, consists of the Mg++-
dependent bimolecular complex C4b,2a (M, approx imately 
280,000) and C3b (M, approximately 176,000). C4b is a t hree-
chain fragment of C4 and C2a, a single-chain fragment of C2. 
C2a is a serine protease as evidenced by inactivation with 
diisopropyl fluorophosphate (DFP) (1] . Viewed by electron 
mic_roscopy, it consists of 2 globul?r domains, one measuring 
42 A in d)amete r and t he other 4 7 A, which are connected by a 
thin 10 A linker segment [2). It is bound to C4b t hrough the 
larger of the 2 domains, suggesting t hat the freely projecting 
domain bears the catalytic site. C2a is noncovalently linked to 
C4b and dissociates spontaneously wit h concomitant loss of 
enzymatic activity, t he complex having a ha lf life at 37oC of 
approximately 3 min . C3b and C4b are covalent ly linked to cell 
surface proteins through ester or amide bonds. Covalent at-
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FIG 1. Schematic representation of assembly of the MAC and its 
cont rol by S-protein. The asterishs denote metastable forms of C5b and 
C5b-7, respectively. 
TABLE I. Properties of the proteins of the membrane attack pathway 
M, Serum Protein M, Subunits S- rate concentration Carbohydrate (!lg/ml) 
C5 191,000 a : 115,000 5,200 8.7S 70 
(J: 75,000 
C5b 180,000 LY ': 104,000 3,000 7.5S 
(J: 75,000 
C6 120,000 Single cha in 4,000 6.0S 64 
C7 110,000 Single chain 6,000 5.6S 56 
C8 151,000 a : 64,000 N.A." 8.0S 55 
(J: 64,000 
y 22,000 
C9 71,000 Single chain' 5,500 4.7S 59 
S-p rote in 83,000 Single chain N.A . 4.0S 505 
"N.A.: Information not ava ilable . 
tachment of C3b occurs when t he internal thioester [3) of 
metastable C3b [4) comes under stress and its carbonyl group 
reacts with a hydroxyl or an amino group of cell surface 
constituents [5). Similarly, a covalent bond is established be-
tween C4b and a reactive surface when the in te rnal thioester 
of metastable C4b enters into a transacylation reaction. 
The C5 convertase of the alternative pathway is C3b,Bb,C3b. 
The catalytic site bearing subunit Bb (M, = 60,000) is a serine 
protease [1] which is derived from Factor B, the structure of 
which has been elucidated by sequencing of the protein [6] and 
of eDNA [7) . The Mg++ -dependent enzyme undergoes rapid 
decay-dissociation at 37oC, its half li fe being 2 min. Using Ni++ 
instead of Mg++ for enzyme formation, the half life at 37°C was 
increased to 11 min and at 4 oc to 32 h [8). The stability of 
C3b,Bb(Ni) was sufticient to allow demonstration of the en-
zyme complex by molecular transport experiments [9) . And 
using t he radioisotope 63Ni , it was found that a single metal ion 
is incorporated into the complex, probably into the Bb subunit, 
and that this metal ion is resistant to chelation by EDT A. 
C3b,Bb has been visualized by electron microscopy and found 
to be simi lar in structure to C4b,2a, except that the two Bb 
domains are of equal size [2]. 
THE MEMBRANE BINDING SITE OF C5b-7 
The assembly of C5b-7 commences with proteolytic activa-
tion of C5 by C5 convertase. At the target cell surface, C5 binds 
to one of the C3b molecules surrounding the C3 convertase 
complex. Suitably presented and modulated by C3b, C5 is 
cleaved and metastable C5b (C5b*) is created, the labile binding 
site of which has specificity for C6. If it collides with a molecule 
of C6, the bimolecular C5b,6 complex is formed [10) . C5b,6 
remains loosely bound to C3b awa iting reaction with C7. 
Upon binding of C7 to C5b,6 on the target cell surface, the 
trimolecular complex undergoes a hydrophilic-amphiphilic 
t ransition in the course of which the metastable membrane 
binding site is generated. C5b-7* leaves the C3b holding posi-
tion and transfers to the surface of the membrane. It overcomes 
the charge barrier of the membrane by ionic interactions prob-
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ably involving its C5b,6 portion and then anchors itself firmly 
in the lipid bilayer by hydrophobic interactions primarily 
through its C7 subunit. The ability of C5b-7 to anchor itself in 
the membrane is due to the acquisition of high-affinity phos-
pholipid-binding sites during the hydrophilic-amphiphilic tran-
sition. Approximately 400 mol of lecithin was found to be firmly 
bound per mol of C5b-7 protein when the complex was formed 
in presence of sodium deoxycholate (DOC) -phospholipid mixed 
micelles and the DOC was removed [11). C5b-7 does not com-
promise membrane function as evidenced by lack of leakiness 
of lipid vesicles or erythrocytes. The lifetime of the transient 
binding site of C5b-7* has been estimated to be less than 10 
ms [12). 
Bound to single bilayer phospholipid vesicles of 200-400 A 
diameter, C5b-7 predominantly appeared as a V-shaped two-
leaf1et structl}re on electron microscopy, which extends approx-
imately 210 A above the vesicle surface and is associated with 
the membrane through an approximately 40 A long stalk [13]. 
This structure is thought to be the dimer of C5b-7 because 
occasionally a single- leaflet structure is visualized on the small-
est vesicles which is likely to be the monomer. Although mon-
omers have been rarely seen, whereas oligomers are the most 
frequent forms of vesicle- or cell -bound C5b-7, there is no 
compelling reason to doubt that C5b-7* is bound in monomeric 
form to membranes, particularly when C8 and C9 are present 
in the reaction mixture. Secondary oligomerization in the mem-
brane may be a consequence of their absence. 
When C5b-7* is formed in the fluid phase, self-aggregation 
occurs and its cytolytic activity is lost. Formation and inacti-
vation proceed according to the following equation: C5b,6 + C7 
<::2 C5b-7* <::2 C5b-7i <::2 (C5b-7i)". (C5b-7i)n constitutes soluble 
protein micelles which exhibit an s-rate of approximately 368 
[13]. Polymerization of C5b-7* is prevented by deoxycholate 
(DOC) micelles which preserve the complex in monomeric 
form, DOC-C5b-7 having an s-rate of approximately 16S (14) . 
In the electron microscope the aggregates are imaged as flower-
like structures in which the C5b-7 monomers remain clearly 
distinguishable [13). Three to six leaflet-like structures can be 
identified per aggregate, each approximately 200 A long, 100 A 
wide and terminating in a pedicle at the center of the flower 
indicating that the pedicellar regions are the sites of hydropho~ 
bic interactions. 
In search for the exact topology of the membrane binding 
site of C5b-7, the possibility was considered that only 1 of its 
subunits contributes the critical hydrophobic structures that 
are responsible for insertion of metastable C5b-7 into lipid 
bilayers. In fact, recent studies [15] have provided strong evi-
dence that it is primarily activated C7 that confers amphiphil-
icity on C5b-7*. It was found that isolated C7, but not C5 or 
C6, has the propensity to undergo hydrophilic-amphiphilic 
transition , to aggregate and to incorporate itself into lipid 
bilayers. Treatment of isolated C7 with 1% DOC at 37oC for 
10 min resulted in complete loss of hemolytic activity and 
dimerization of the protein. The modified C7 has a M, of 
230,000, which is twice that of native C7, it is more negatively 
charged than native C7, and it contains 18% more {J-pleated 
sheet structure [15). The dimer possesses hydrophobic surface 
domains as evidenced by its ability to bind approximately 82 
moles of DOC per mole of dimer and by its prompt precipitation 
from solution on removal of the detergent. That the C7 dimer 
is also endowed with phospholipid-binding sites was concluded 
from its ability to become inserted into lipid bilayers. Dimeric 
C7 bound to DOC-phospholipid-mixed micelles remained as-
sociated with the lipid vesicles, which formed on removal of the 
detergent, and could not be dissociated by 2 M NaCI. Electron 
microscopy showed the protein incorporated into the lipid 
bilayer and the vesicles leaky to stain penetration [15] . 
Taken together, the available information suggests that, in 
the physiological pathway, C5b,6 acts on C7 much in the 
manner DOC does: It converts C7 to an activated, amphiphilic 
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state in which it expresses polar and apolar binding sites which 
a re concea led in the native molecule. The binding sites of C7 
to be distinguished are these: Native C7 has a binding site for 
C5b,6 which may be the same as t hat for native C5. C5b,6-
bound a nd activated C7 has mul tiple phospholipid binding sites, 
which in t he aggregate constitute the hydrophobic membrane 
binding site of C5b-7*. It expresses a largely polar protein 
binding site by means of which C5b-7 can dimerize or possibly 
react with C8. C7 thus emerges as a highly versatile molecule 
in t he MAC assembly a nd as t he subuni t t hat supplies the 
ini t ia l anchor of the forming complex in t he target membrane. 
STRUCTURE AND FUNCTION OF THE 
TETRAMOLECULAR C5b-8 COMPLEX 
Native C8 has no detectable a ffinity for membranes and is 
t herefore ent irely dependent on the mediating function of C5b-
7 which determines the site of membrane attack and serves as 
C8 receptor. Membrane-bound C5b-7 not only binds C8, but it 
a lso affords its insertion into the membrane. It t hus has at 
least 2 distinct functions with respect to C8 and the question 
arises as to which of its 3 subuni ts are involved in ligand 
binding and in the subsequent processing of C8. 
Already prior to fusing into the t ight MAC complex, t he 5 
precusor proteins express some stereochemical affinity for each 
other . Reversible interactions occur between C5 and C6; C5 
and C7; C5 and C8; and C8 and C9 [16). Accordingly, t he 
binding site for C8 on the recepto r may be situated on its C5b 
subuni t, whereas the recognition s ite on C8 for the receptor 
has been located to the {3-chain of C8 [1 7,18]. This chain was 
shown to bind to C5b-7 in absence of the a --y subunit and with 
the same affi ni ty as native C8. The a--y subuni t did not attach 
to C5b-7 without the mediation of the {:1-chain [18, 19] . T his 
initial contact probably brings a second site of t he receptor into 
play which enables C8 to unde rgo t he necessary conformational 
rearrangement to allow the a-')' subuni t to penetrate into t he 
hydrophobic core of the lipid bilayer [20). 
Electron microscopy of C5b-8 bound to sma!l phospholipid 
vesicles visualized monomeric C5b-8 as a 250 A long and 50-
140 A wide rod-like structure wi t h a rather polymorphic ap -
pearance (21]. The C5b,6 subuni t was detected at t he end of 
the rod, distal to t he lipid-binding site, using avidin-coated gold 
probes recognizing biotinyl C5b,6. 
There are 2 distinct ways in which C5b-8 acts on C9, namely 
binding and polymerization; both reactions proceed irrespective 
of whether C5b-8 is membrane-bound or free in the fluid phase. 
Binding of C9 occurs via the C8 portion of C5b-8, as evidenced 
by the facts t hat C9 cannot bind to C5b-7, t hat binding to C5b-
8 is inhibited by ant i-CS and t hat C8 and C9 interact in free 
solut ion [16). Soluble C8 binds only 1 molecule of C9 even 
when C9 is in considerable mo!.ar excess. This fact is in cont rast 
to the ability of C5b-8 to bind mul t iple C9 molecules, which, of 
course, is due to C9 polymeri zation. 
The penet ration of C5b-8 in to the membrane and its influ-
ence on the order of the bilayer were measured on planar lipid 
bilayers doped with spin -labels using electron paramagnetic 
resonance spectroscopy [22]. These studies showed that 
whereas C5b-7 interacted strongly with t he ion ic part of the 
bilayer and penetrated only slight ly into the hydrophobic re-
gion, C5b-8 penetrated into the hydrophobic phase more deeply. 
Insertion caused an increase in disorder of the membrane lipids 
which means that the fatty acyl chains adopted a wider distri-
bution of angles with respect to each other t han they would in 
a normal bilayer structure. This reorientation of the ordered 
bilayer lipids into domains more micella r in nature is due to 
strong binding of phospholipid molecules to the inserted poly-
peptides of C5b-8. Direct lipid-binding studies employing ra-
diolabeled lecithin showed t hat approximately 800 moles of 
phospholipid can be bound per mole of C5b-8, which is about 
twice as much as can be bound by C5b-7 [11] . Studies designed 
to determ ine the parts of C5b-8 most int imately in contact with 
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the in terior of a membrane revealed t he a-chain of C8 [23] to 
be primarily interacting wit h the hydrocarbon phase. 
STRUCTURE AND FUNCTION OF THE C5b-9 
COMPLEX 
The MAC is heterogeneous with respect to size and compo-
sition. H eterogenei ty is due to variation in C9 content and 
secondary aggregat ion of C5b-9. Nevertheless, t he basic com-
position of the MAC is described by the formula 
C5b~oC6~oC7~oC8~oC9n, where n can vary between 1 and 18. 
Hence, t he minimum M, of the MAC ranges between 660,000 
and 1,850,000. 
There is now very little doubt that the electron microscopic 
image of the ring-like or cylinder-like membrane lesion caused 
by complement is evoked primarily by poly C9 (24]. It is not 
known how C5b-8 causes C9 polymerization. C8 in solut ion has 
one C9-binding site and C8-C9 association is reversible (K" -
107 M - 1) [24], whereas cell-bound C8 can mediate t he binding 
of many C9 molecules and that association is virtually irrever-
sible (K"- 1011 M- 1) (12] . Binding of a molecule of C9 to C5b-
8 might facilitate high affinity C9-C9 interaction and the energy 
derived from t hat interaction might effect constrained unfold-
ing of monomeric C9 (long axis - 80 A) to t he poly C9 subunit 
(long axis - 160 A) with exposure of hydrophobic regions that 
insert themselves into the membrane. Polymerization of the 
C9 oligomers continues unt il closure of the tubule occurs or the 
supply of monomeric C9 is exhausted. It is t he C-terminal 
region of the unfolded C9 that inserts into the hydrocarbon 
phase of t he membrane [25]. 
The poly C9 tubule of the membrane-bound MAC extends 
120 A above the surface of the membrane, it has an inner 
diameter of 110 A and it terminates at its upper , hydrophil ic 
end in a 30 A t hick annulus which has an outer diameter of 
210 A [21,26]. The C5b-8 subunit appe~rs firmly attached to 
the poly C9 tubule and extends 160- 180 A above its annulus as 
a 50-140 A wide elongated struct.ure [21]. The total length of 
the structure is thus 280-300 A above the surface of the 
membrane. 
The structure of the MAC varies great ly with the supply of 
C9, i.e., with t he molar C9/C5b-8 ratio and also with the 
topographical distribution of C5b-8 on t he cell surface. When 
the MAC was assembled on vesicles or erythrocytes and the 
molar C9/C5b-8 rat io was 1 or 3, no poly C9 was detectable by 
sodium dodecyl sulfate- (SDS) polyacrylamide gel electropho-
resis (27] and no complement membrane lesions were seen on 
electron microscopy (24]. Instead, large protein aggregates were 
observed which probably represented a C5b-9 network main-
tained by C9-C9 interactions. The poly C9 content of the MAC 
was found to be directly proportional to the molar C9/C5b-8 
ratio. When this ratio was 6 or 12, the percentage of C9 present 
as poly C9 was 35 and 72, respect ively [27]. At these ratios 
discrete ring structures were observed on the cell surface by 
elect ron microscopy which appeared unaggregated and well 
separated from each other [24]. Examination of DOC-solubi-
lized MAC for poly C9 content after molecular sieve chroma-
tography in presence of DOC, detected the greatest amoun t in 
the relat ively low M , unaggregated material (27). 
It thus appears that even within the lipid bilayer C5b-9 will 
either aggregate to larger clusters when the C9 mult iplicity is 
low, or form poly C9 containing monomers when the C9 mul-
tiplicity is high. Obviously, SDS-resistant poly C9 cannot be 
regarded as obligatory constituent of the MAC and C5b-9 does 
not necessarily manifest itself as t he typica l ul trastructural 
membrane lesion. The functional significance of oligomeric C9 
as subunit of the MAC requires investigation. 
The MAC has a greater phospholipid-binding capacity than 
its precursor complexes. It possesses high-affinity-binding sites 
for 1,400 mol of lecithin per mol of complex [11] . It also binds 
other phospholipids but not cholesterol. 
The si ze of t he functional t ransmembrane pore produced by 
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C5b-9 is highly variable and dependent on t he experimental 
condit ions. T he smallest C5b-9 pore was found to have a 
diamete r of 7 A and t he la rgest of more t han 55 A [28-30]. T he 
size increases wit h C5b-9 density on a target membrane and 
with the C9 to C5b-8 ratio (28]. At very high complement dose 
t he maximum diameter of the pore was 110 A using human 
complement and 70 A using guinea p ig complement. 
SPONTANEOUS POLY C9 FORMATION 
Although C9 is a wate r soluble glycoprotein , it has t he 
propensity to aggregate in isolated form and t hen to undergo a 
hydrop hilic-amphiphilic t ransition which resul ts in cyclic po-
lyme rization. T he outcome of t his process is a tubular structure 
which has a hydrophilic ann ulus of 30 A thickness at one end 
and which is lipophilic at t he other end. T he height of the 
tubule is 160 A, t he inner diameter 100 A and t he wall t hickness 
app roximately 20 A (Fig 2). T hrough the lipophilic end t he 
form ing tubule is capable of inserting itself into t he membrane 
of phospholipid vesicles and to render t hem leaky. The hydro-
phobic portion of t he poly C9 tubule corresponds to t he C-
terminal region (C9b) of its subunits. Twelve to 18 molecules 
ofC9 are incorporated-into tubular poly C9 which is also defined 
as an approx imately 1.1 million dalton complex t hat is resistant 
to dissociation by SDS and reducing agents. Poly C9 possesses 
more ,6-pleated sheet structure than native, monomeric C9 and 
it expresses antigenic determinants that are not detectable on 
its precursor (24,32]. 
Because the dimensions of native C9 are 80 X 55 A and 
because t he length of t he poly C9 cylinder is 160 A, it is assumed 
t hat C9 during po lymerization undergoes constrained un fo ld-
ing. Unfo ldi ng is preceded by an ini t ia l reversible association 
of severa l C9 molecules which can be demonstrated by ul t ra-
centrifugation under app ropriate condit ions. The 160 A long 
un fo lded C9 monomers then assoc iate laterally wit h each other 
like staves of a barrel and polymerization terminates wit h 
closure of t he circula r structure. Native C9 has some affi nity 
fo r phospholi pids. At 4 oc it enters into ionic interaction wit h 
phospholip id which faci li tates subsequent hydrophobic inter-
action of polyme rizing C9 wit h lipid vesicles at 37oC (32] . 
FIG 2. Ultrastructure of poly C9 made from isolated monomeric C9 
by prolonged incubation at 37•c. Poly C9 is visualized as stai n-fi lled 
tubule with an inner diameter of 11 nm (top views a re imaged as rings) 
and a length of 16 nm (side views, black arrows). T he a nnulus at one 
end of tubu le is approximately 3 nm thick and has an oute r dia meter 
of 21 nm (blach arrowhead). The other end of the tubules consists of a 
4 nm long hydrophobic segment through which t he tubules fo rm side-
by-side aggregates with overlapping a reas (white arrows). Bars: 40 nm 
[31]. 
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Insert ion of fo rming poly C9 into t he membranes of lipid 
vesicles caused marker release and stain penetration when 
analyzed by electron microscopy. 
The remarkable phenomenon of poly C9 fo rmatio n raises 
mechanistic questions, especially whether enzymes are involved 
in spontaneous C9 polymeri zation and how C5b-8 mediates it. 
Zinc was part icularly effect ive in t hat it permitted at a concen -
t ration of 50 J.LM rapid polymerization even in presence of 150 
mM NaCI. The poly C9 rapidly generated under opt imal con-
dit ions had the typical ult rastructural appearance. Gleaning 
from these observations what t he specific function of C5b-8 
might be, one might say t hat C5b-8 induces the ini t ial assoc i-
ation of several C9 molecules, probably 2, under conditions 
(0.15 M NaCl, 0.01 M EDTA, pH 7.4) t hat would not allow t his 
reaction to occur in its absence. C5b-8 reduces t he activation 
energy of C9 polymerization and greatly enhances the rate of 
polymerization thus acting as a catalyst. Finally, whereas po-
lymerizing C9 can attack lipid vesicles in absence of C5b-8, it 
cannot lyse biological membranes unless C5b-8 is present on 
their surface. 
It is of considerable interest that killer lymphocytes produce 
and insert into t he membrane of target cells tubular structures 
that resemble poly C9. T his was fi rst reported by Dourmashkin 
et al (33] who examined cells after lysis by t he ant ibody 
dependent cellular cytotoxicity reaction, and who found the 
human lymphocyte-derived cylinders to have an inner diameter 
of 160 A. Subsequent ly, similar tubular structures were fo und 
to be produced by cloned mouse natural killer cells and cytolytic 
T cells [34]. The precursor proteins which are contained in the 
cytoplasmic dense granules of these cells diffe r in size from C9. 
CONTROL OF MAC FORMATION 
T he S-protein of plasma [31] competes with membrane lipids 
fo r the metastable-binding site of C5b-7, and by binding to the 
complex, it prevents its attachment to the cell surface. The 
inhibit ion constant, K; , is 39 J.Lg/ml which is less than 1/10 of the 
plasma concent ration of t he protein [35]. Its function appears 
to be to p rotect cells adjacent to t he site of complement acti-
vation from accidental attack. The resul tant SC5b-7 complex 
contains 3 molecules of S-protein (M, = 80,000), has an s-rate 
of 18.58 and a M, of 668,000. T he hydrophilic complex binds 
C8 and 3 molecules of C9 to form SC5b-8 and SC5b-9 (M, 
1,030,000) (31] . All 3 complexes contain neoant igens t hat are 
not detectable in the precursor proteins and that are distinct 
fro m t he neoant igens of poly C9. In addit ion to blocking the 
membrane-binding site, S-prote in also prevents polymerization 
of C9 [36]. 
KILLING OF NUCLEATED CELLS 
Little is known about the precise mechanism of killing of 
nucleated cells by complement. The fact is, t hey are susceptible 
to t he lytic action of the MAC, but much less so than erythro-
cytes. A mechanistic analysis showed t hat the killing of meta-
bolically-active nucleated cells is a multi-hit process [37]. T here 
may be several reasons fo r the relative resistance of t hese cells 
including inactivation or ejection of cell surface-bound compte: 
ment proteins, the chemical composition of their outer cell 
membrane and repair of membrane damage. In short, nucleated 
cells can defend themselves against complement attack at least 
to a certain extent. 
In a recent study, Raji cells were employed as targets, 86Rb 
release was used to detect the initial membrane lesion and 5 1Cr 
release as a measure of cell death. Since Raji cells are mild 
ac~ ivators of the alternative pathway in abse nce of ant ibody, 
t h1s pathway was ut ilized with properdin and C9 in diffe ren-
tia lly radiolabeled form (Fig 3) [38). Activation proceded slowly 
as indicated by properdin uptake which was maximal only at 1 
h. C9 uptake was considerably slower and approached a plateau 
of 90,000 molecules per cell after 4 h. Membrane leakiness 
became noticeable during the first 30 min and 86Rb release was 
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FIG 4. Effect of puromycin t reatment on the kinetics of alternative 
pathway dependent lys is of Raji cells. Raji cells were cultured 17 h in 
absence or presence of puromycin (20 llg/ml culture) . Cells were 
washed, labeled with "'Cr, and incubated with 50 Ill C4-depleted serum. 
Spontaneous release at 3 h was 24.5% for puromycin-treated cells and 
4.5% for control cells [38]. 
complete after 2 h when on ly 10% of the ce lls had died. Cell 
death was considerably delayed, approaching 50% after 8 h and 
100% after 20 h. However, when protein synthesis was inhibited 
by puromycin, ce ll ki lling was complete within 2 h (Fig 4). 
Under such condi tions, t he kinetics of m;Rb and "'Cr release 
became similar. It appears that the forming MAC produces an 
ini tia l membrane lesion which a llows escape from t he cyto-
plasm of small molecules but not of macromolecules. The cell 
can tolerate t he init ia l membrane damage over a pe riod of time 
utilizing metabolic processes t hat are inhibitable by certain 
antibiotics. When t he compensatory repair mechanisms fail, 
cell death follows rapidly t he production of t he initial les ion. 
THE KILLER MOLECULE OF COMPLEMENT 5ls 
The cell defense or membrane repair mechanisms can be 
over~helm~d when t he rate of MAC uptake is high. Using 
reactive lysis (C5b,6, C7, C8, and C9) and Raji cells pretreated 
with 14C phospholipid, a very high rate of MAC uptake could 
be achieved which was paralleled by t he rate of cell lysis [39] . 
Twenty-five percent cell killing occurred within 5 min when 
40,000 C5b-9 were bound per cell and 70% when t his number 
was 400,000. Under t he latter conditions, 15% of the 14C phos-
pholipid was released and found in association with C5b-9 
protein as ejected membrane vesicles. Whether in addition to 
ejection lipid bound C5b-9 was a lso endocytosed before cell 
death occurred, was not determined. 
Nucleated cells have the capacity to respond to complement 
attack within minutes with increased lipid synthesis and lipid 
release [40]. The newly synthesized lipid may, in part, be 
utilized by the cell to reconstitute its outer membrane from 
which fragments containing channels were ejected. The cell 
may also change its lipid composition and t hereby become more 
resistant to lysis by complement. 
Many questions regarding complement attack of nucleated 
cells remain cu rrently unanswered. Specifically, do t hese cells 
have species-specific membrane regulatory proteins which exert 
negative regulatio n on t he C3/C5 convertases such as DAF 
(decay-accelerating factor). DAF exercises powerful control 
over the MAC generating enzymes on erythrocytes [41] . Is the 
poly C9 channel or t he C5b-9 network more effective in bringing 
about lethal membrane damage despite cellular defense and 
membrane repair? Is t here a critical number of C5b-9 com-
plexes or a critical rate of uptake that will achieve cell death? 
These considerations are important not only from t he point of 
view of cell biology and immunology, but a lso for t he design of 
potential immunotherapeutic agents t hat utilize host comple-
ment, such as conjugates of antitumor monoclonal antibody 
and cobra venom factor (42 ]. 
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